Malignant Mesothelioma: Canadian Perspective and Research Directions
Author Information
Author(s): Lee C.W., Martin J., MacRae R., Tsao M.S., Nguyen E., Johnston M., Baas P., Laure S., Feld R., Murray N., Shepherd F.A.
Primary Institution: BC Cancer Agency – Fraser Valley Centre
Conclusion
A national research strategy is needed to address the increasing incidence of malignant pleural mesothelioma in Canada.
Supporting Evidence
- Malignant mesothelioma cases in Canada have increased dramatically due to asbestos exposure.
- Chemotherapy is now a standard treatment for advanced mesothelioma, but its survival benefit is modest.
- A national dialogue is necessary to develop a clinical research strategy for mesothelioma.
Takeaway
Doctors are trying to figure out the best ways to treat a type of lung cancer caused by asbestos, and they want to work together across Canada to find better solutions.
Methodology
The study involved a symposium where physicians and researchers discussed the current management and future research directions for malignant pleural mesothelioma.
Potential Biases
Uncertainties and biases related to radical surgery among thoracic surgeons may affect trial outcomes.
Limitations
The scope of clinical research is limited by the frequency of mesothelioma and the availability of specialist resources across Canada.
Participant Demographics
Participants included 52 physicians and researchers from various specialties related to mesothelioma treatment.
Want to read the original?
Access the complete publication on the publisher's website